Remove Antibody Remove FDA Approval Remove Life Science Remove RNA
article thumbnail

Krystexxa Chronic Gout Medication Gets Expanded FDA Approval

XTalks

Over time, even the use of Krystexxa can lead to the development of antibodies against it, reducing its effectiveness. Early data also showed that methotrexate could prevent the formation of anti-drug antibodies. Related: Vtama (tapinarof) Cream Gains FDA Approval for the Treatment of Plaque Psoriasis in Adults.

article thumbnail

Complex Medicines: A multi-billion-pound addition to the UK life sciences industry

pharmaphorum

Drugs harnessing the potential of modified RNA, antisense and siRNA oligonucleotides, antibody–drug conjugates and nanomedicines will become as important as today’s ‘small molecule’ drugs, reaching potential market values into the hundreds of billions – if the potential can be realised through innovation support and industry collaboration.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug discovery hotspots: What is the secret to Switzerland’s success? (p1)

Drug Discovery World

DDW’s Diana Spencer takes a closer look into why Switzerland is such a life sciences powerhouse and how Swiss researchers are advancing new technology and tackling modern health challenges. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

article thumbnail

GSK’s Injectable HIV Treatment Cabenuva Garners FDA Approval

XTalks

Although TaiMed Biologics’ antibody drug Trogarzo is an intravenous formulation that is administered once every 14 days, it must be used in conjunction with other antiretroviral drugs. Patients in the studies were virologically suppressed (HIV-1 RNA less than 50 copies/milliliter) prior to initiation of treatment with Cabenuva.

article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

New FDA-Approved Treatments For HIV HIV treatment involves the administration of combined antiretroviral therapy (ART) to effectively suppress the viral load, maintain or enhance immune function and reduce the risk of opportunistic infections and cancers commonly associated with HIV. aiming to end the HIV epidemic by 2030.

article thumbnail

LabCorp’s Innovative High-Speed COVID-19 Test Gets Emergency Use Authorization from the FDA

XTalks

LabCorp – a leading global life sciences company based in Burlington, North Carolina that focuses on advancing health and guiding patient care decisions – announced that it is the first commercial laboratory to receive an EUA from the FDA for the new, innovative, high-speed test.

Reagent 98
article thumbnail

The evolution of the RNA therapeutics landscape 

Drug Discovery World

Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics. However, the RNA landscape has drastically changed in recent years and we now know that the molecule is more than just a transient, linear carrier of information.

RNA 59